In summary, the findings of this present study demonstrated that HGMB1 is a direct target gene of miR‐34c, and miR‐34c might be a novel therapeutic strategy in the management of atherosclerosis by suppressing the expression of HGMB1, as well as its downstream pro‐inflammatory factor such TNF‐a and NF‐kB. Here, NFKB1 is linked to atherosclerosis.